MD Stock — Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc. (MD)

Updated October 16, 2026.

MD is a Stock. Total return is 412.4% over the past 31.1 years, 1705.1 points behind SPY at 2117.5%.

Pediatrix Medical Group provides clinical care services focused on newborn, maternal-fetal, and pediatric subspecialty medicine across the United States, operating through a network of affiliated physicians and clinicians who deliver care in hospital settings including neonatal intensive care units and maternal-fetal medicine services. The company does not currently have an established distribution schedule.

MD performance versus SPY

Price and return data through 2026-10-16.

Total return is 412.4% over the past 31.1 years, 1705.1 points behind SPY at 2117.5%. Over the past year its total return — price change plus distributions reinvested — is 69.0%. Its deepest 1-year drawdown was 23.7%.

MD key facts

Asset type

Stock

Asset class

Equity

Inception date

09/20/1995

Distribution frequency

None

Last close

$27.38 (as of 2026-10-16)

Market cap

$2,224,714,560

Average volume

534997.0

Beta

0.61

Payout ratio

0.0%

P/E ratio

12.92

Forward P/E

9.2937

EPS

$2.12

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MD risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 23.7%.

Who may consider MD — and who may not

It is a weaker fit for investors who need monthly cash flow (MD does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MD

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions